Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

ABSTRACT:

Context

Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM).

Objective

Our objective is to describe the effects of canagliflozin on bone mineral density (BMD) and bone biomarkers in patients with T2DM.

Design

This was a randomized study, consisting of a 26-week, double-blind, placebo-controlled period and a 78-week, double-blind, placebo-controlled extension.

Setting

This study was undertaken in 90 centers in 17 countries.

Patients

Patients were aged 55-80 years (N = 716) and whose T2DM was inadequately controlled on a stable antihyperglycemic regimen.

Interventions

Canagliflozin 100 or 300 mg or placebo were administered once daily.

Outcome and measures

BMD was assessed using dual-

SUBMITTER: Bilezikian JP 

PROVIDER: S-EPMC4701848 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature